March 31 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES POSITIVE FINAL DATA IN 2ND LINE METASTATIC NSCLC PATIENTS REFRACTORY TO ANTI-PD-(L)1 THERAPY AT EUROPEAN LUNG CANCER CONGRESS 2023
- IMMUTEP LTD - EFTI PLUS PEMBROLIZUMAB ACHIEVED MOS OF 9.9 MONTHS AND A 39% OS RATE AT 21 MONTHS
- IMMUTEP LTD - 83% OF PATIENTS STUDIED FOR TUMOUR GROWTH KINETICS SHOWED DECELERATION OF TUMOUR GROWTH OR SHRINKAGE OF TUMOURS
- IMMUTEP LTD - ORR OF 8.3%, DCR OF 33.3%, AND 6-MONTH PFS RATE OF 25% IN ALL-COMER PD-L1 PATIENT POPULATION
- IMMUTEP LTD - ORR OF 33.3%, 6-MONTH PFS OF 50%, AND MOS NOT YET REACHED FOR PATIENTS WITH HIGH PD-L1 EXPRESSION
- IMMUTEP LTD - COMBINATION OF EFTI PLUS PEMBROLIZUMAB WELL TOLERATED IN DIFFICULT-TO-TREAT PATIENT POPULATION WITHOUT ANY NEW SAFETY SIGNALS
- IMMUTEP LTD - THERE WAS NO TREATMENT DISCONTINUATION DUE TO ADVERSE REACTIONS
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $337.6M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $244.5K | 1.043M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 392012 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 126850 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |